1132642-58-0
1132642-58-0
Chemical Structure
Dapoxetine-d6
- CAS No.: 1132642-58-0
- Formula:C21H17D6NO
- Molecular Weight:311.45
IUPAC Name: (S)-N,N-bis(methyl-d3)-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine
InChIKey: USRHYDPUVLEVMC-PVKQDMRYSA-N
SMILES: [2H]C([2H])([2H])N(C([2H])([2H])[2H])[C@H](C1=CC=CC=C1)CCOC2=CC=CC3=C2C=CC=C3
Biological Activity: Dapoxetine-d6 is the deuterium labeled Dapoxetine[1]. Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE)[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dapoxetine-d6 | Dapoxetine-d6 is the deuterium labeled Dapoxetine. Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dapoxetine (Standard) | ≥98% | Dapoxetine (Standard) is the analytical standard of Dapoxetine. This product is intended for research and analytical applications. Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dapoxetine | Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Muammer Kendirci, et al. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Manag. 2007 Jun;3(2):277-89. [Content Brief]
